ICCM News and Press, IceCure Medical Ltd. From 11/03/25

IceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival PR Newswire 5-year overall survival (OS) rate for stereotactic body radiation therapy (SBRT) followed by cryoablation was 7...

IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances PR Newswire FDA's marketing authorization for ProSense® for low-risk breast cancer received following the TME Fall Summit—Mar...

IceCure Medical to Attend the 2025 Maxim Growth Summit PR Newswire IceCure recently achieved a significant milestone—ProSense® Cryoablation system became the first and only medical device to be granted FDA marketing authorization for the local treatment of breast c...

2025-10-06 11:52:51 ET IceCure Medical Ltd (ICCM) U.S. Food and Drug Administration's Marketing Authorization for ProSense Cryoablation Call... Read the full article on Seeking Alpha For further details see: IceCure Medical Ltd (ICCM) U.S. Food And Drug Administration's Mark...

2025-10-06 11:25:19 ET IceCure Medical Ltd - Special Call Company Participants Eyal Shamir - CEO & Director Shad Good Ronen Tsimerman - CFO & COO Conference Call Participants Michael Polyviou - EVC Group Inc. Anthony Vendetti - Maxim...

IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care PR Newswire ProSense ® cryo...

IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above PR Newswire ProSense® is the first and only medical device to be granted FDA marketing authorization for the local treat...

IceCure's ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented PR Newswire IceCure's exclusive workshop was filled to capacity – Unlocking De-Esc...

IceCure's ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented PR Newswire Presentations from 5 Key Opinion Leaders on ProSense® cryoablation including 3 independent studies on breast canc...

2025-09-18 08:52:09 ET More on IceCure Medical IceCure Medical Ltd (ICCM) Q2 2025 Earnings Call Transcript IceCure Medical GAAP EPS of $0.12, revenue of $1.25M Seeking Alpha’s Quant Rating on IceCure Medical Historical earnings data for IceCure Medical...